A comparative study on tumour response, intrathoracic symptom palliation and toxicities in locally advanced inoperable non-small cell lung cancer patients receiving palliative chemoradiation versus radiation alone
DOI:
https://doi.org/10.18203/2320-6012.ijrms20251633Keywords:
Unresectable non-small cell lung cancer, Palliative chemoradiation, Nab-paclitaxel, Intrathoracic symptom palliationAbstract
Background: Locally advanced unresectable non-small cell lung cancer (LA-NSCLC) is a key focus in research, as it presents significant treatment challenges, with low survival rates despite progress in radiotherapy and systemic therapies. This study compares two palliative regimen for LA-NSCLC, one with radiation alone the other arm as concurrent chemoradiation therapy (CCRT) with nab-paclitaxel.
Methods: A Randomised Controlled Trial was conducted in the Department of Radiation Oncology, Regional Institute of Medical Sciences, Imphal from July 2022 to June 2024. Sample size of 96 was calculated. In the Control Arm (Arm A), patients were treated with radiation alone at the dose of 36 Gy/12# and in the Study Arm (Arm B), CCRT was given at 40 Gy/20 with nab-paclitaxel given as a weekly dose. The primary endpoint is to see the tumour response, intrathoracic symptom palliation and treatment toxicities between the two arms. Secondary endpoints include progression-free survival (PFS).
Results: Our study has a better overall response rate in Arm B compared to Arm A and the most effectively palliated symptoms in our study were chest pain and shortness of breath. Arm B exhibited more pronounced acute and late radiation toxicities which were manageable. The median PFS was 8 months in Arm A and 13 months in Arm B.
Conclusions: Overall response rate after completion of treatment was higher in palliative concurrent chemoradiation group as compared to palliative radiation therapy group, but in totality, the two palliative lung cancer treatment regimens were almost equal in efficacy in terms of intrathoracic symptom palliation and toxicity.
Metrics
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. DOI: https://doi.org/10.3322/caac.21834
Collins LG, Haines C, Perkel R, Enck RE. Lung Cancer: Diagnosis and Management. Am Fam Physician. 2007;75(1):56–63.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. DOI: https://doi.org/10.3322/caac.20107
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;1;28(4):1-21. DOI: https://doi.org/10.1093/annonc/mdx222
Shim J, Brindle L, Simon M, George S. A systematic review of symptomatic diagnosis of lung cancer. Fam Pract. 2014;31(2):137-48. DOI: https://doi.org/10.1093/fampra/cmt076
Alexander M, Kim SY, Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer. Lung. 2020;198(6):897-907. DOI: https://doi.org/10.1007/s00408-020-00407-5
Li H, Li J. Effectiveness of palliative care for non-small cell lung cancer. Exp Ther Med. 2016;12(4):2387-9. DOI: https://doi.org/10.3892/etm.2016.3621
Chang XJ, Wang ZT, Yang L. Consolidation chemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis. Mol Clin Oncol. 2016;5(2):271-8. DOI: https://doi.org/10.3892/mco.2016.910
Lehman M, Bernard A, See A, King M, Michael M. A randomized phase 3 trial of palliative radiation therapy versus concurrent chemotherapy and palliative radiation therapy in patients with good performance status, locally advanced or metastatic non-small cell lung cancer with symptoms due to intrathoracic disease who are not suitable for radical chemo-radiation therapy: results of the trans-Tasman radiation oncology group 11.03 trial. Pract Radiat Oncol. 2021;11(4):252-63. DOI: https://doi.org/10.1016/j.prro.2020.11.009
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055-62. DOI: https://doi.org/10.1200/JCO.2011.39.5848
Tsuchiya-Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, et al. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. Oncologist. 2020;25(6):475-891. DOI: https://doi.org/10.1634/theoncologist.2019-0746
Muers MF, Round CE. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax. 1993;48(4):339-43. DOI: https://doi.org/10.1136/thx.48.4.339
Christodoulou M, Bayman N, McCloskey P, Rowbottom C, Faivre-Finn C. New radiotherapy approaches in locally advanced non-small cell lung cancer. Eur J Cancer. 2014;50(3):525-34. DOI: https://doi.org/10.1016/j.ejca.2013.11.027
Higginson DS, Chen RC, Tracton G, Morris DE, Halle J, Rosenman JG, et al. The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2012;1;84(3):385-92. DOI: https://doi.org/10.1016/j.ijrobp.2012.04.045
Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, Lin ZZ, et al. The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases. PLoS One. 2015;10(12):145936. DOI: https://doi.org/10.1371/journal.pone.0145936
Bezjak A, Dixon P, Brundage M, Tu D, Palmer MJ, Blood P, et al. Clinical trials group of the national cancer institute of Canada. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002s;54(3):719-28. DOI: https://doi.org/10.1016/S0360-3016(02)02989-9
Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25(1):45-52. DOI: https://doi.org/10.5114/wo.2021.103829
Prasad KT, Kaur H, Muthu V, Aggarwal AN, Behera D, Singh N. Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients. World J Clin Oncol. 2018;10;9(7):140-7. DOI: https://doi.org/10.5306/wjco.v9.i7.140
Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, Rodríguez-Martínez Á, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics and survival. Transl Lung Cancer Res. 2021;10(1):506-18. DOI: https://doi.org/10.21037/tlcr.2020.03.40
Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. Eur Respir J. 2004;24(6):898-904. DOI: https://doi.org/10.1183/09031936.04.00113603
Lung Cancer Early Detection, Diagnosis and Staging. Available at: https://www.cancer.org. Accessed on 21 November 2024.
Spiro SG, Gould MK, Colice GL; American College of Chest Physicians. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3):149-60. DOI: https://doi.org/10.1378/chest.07-1358
Bairwa SC, Gothwal RS, Ram B, Gupta S, Meena C. Comparative study of two thoracic radiotherapy schedules for palliation of symptom, radiological response and acute toxicities in advanced non-small cell lung cancer. Asian Pac J Cancer Care. 2021;2;6(2):159-65. DOI: https://doi.org/10.31557/apjcc.2021.6.2.159-165
Simpson JR, Francis ME, Perez-Tamayo R, Marks RD, Rao DV. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys. 1985;11(4):751-8. DOI: https://doi.org/10.1016/0360-3016(85)90307-4
Michael M, Wirth A, Ball DL, MacManus M, Rischin D, Mileshkin L, et al. A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC. Br J Cancer. 2005;19;93(6):652-61. DOI: https://doi.org/10.1038/sj.bjc.6602759
Burmeister BH, Michael M, Burmeister E, Cox S, Lehman M, Wirth A, et al. A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans-Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol. 2011;6(12):2076-82. DOI: https://doi.org/10.1097/JTO.0b013e31822d53a9
Wang S, Liang Q, Chi Y, Zhuo M, An T, Duan J, et al. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. Thorac Cancer. 2020;11(5):1149-59. DOI: https://doi.org/10.1111/1759-7714.13356
Atagi S, Kawahara M, Tamura T, Noda K, Watanabe K, Yokoyama A, et al. Japan Clinical Oncology Group (JCOG9812). Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group. J Clin Oncol. 2005;35(4):195-201. DOI: https://doi.org/10.1093/jjco/hyi060
Dawe DE, Christiansen D, Swaminath A, Ellis PM, Rothney J, Rabbani R, et al. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2016;99:180-5. DOI: https://doi.org/10.1016/j.lungcan.2016.07.016
Wu K, Zhu L, Wang J, Pan K, Wang B, Li X, et al. A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer. J Thorac Dis. 2019;11(11):4529-37. DOI: https://doi.org/10.21037/jtd.2019.10.81
Abbas MN, Ayoola A, Padman S, Kumar R, Leung J, Ullah S, et al. Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up. J Thorac Dis. 2019;11(10):4241-8. DOI: https://doi.org/10.21037/jtd.2019.09.56
Schytte T, Hansen O, Stolberg-Rohr T, Brink C. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. Acta Oncol. 2010;49(7):1058-60. DOI: https://doi.org/10.3109/0284186X.2010.504736
Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, et al. Cardiac Radiation Dose, Cardiac Disease and Mortality in Patients With Lung Cancer. J Am Coll Cardiol. 2019;73(23):2976-87. DOI: https://doi.org/10.1016/j.jacc.2019.03.500
Sarihan S, Kayisogullari U, Ercan I, Engin K. Randomized phase 2 study of radiotherapy alone versus radiotherapy with paclitaxel in non-small cell lung cancer. J Int Med Res. 2004;32(4):375-83. DOI: https://doi.org/10.1177/147323000403200405
Downloads
Published
How to Cite
Issue
Section
